vs

Side-by-side financial comparison of BGC Group, Inc. (BGC) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

BGC Group, Inc. is the larger business by last-quarter revenue ($955.5M vs $622.0M, roughly 1.5× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 8.4%, a 26.0% gap on every dollar of revenue. On growth, BGC Group, Inc. posted the faster year-over-year revenue change (43.8% vs 4.8%). Over the past eight quarters, BGC Group, Inc.'s revenue compounded faster (48.2% CAGR vs 4.6%).

BGC Group, Inc. is an American global financial services company based in New York City and London. Originally formed as part of the larger Cantor Fitzgerald organization, BGC Partners became its own entity in 2004.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BGC vs RPRX — Head-to-Head

Bigger by revenue
BGC
BGC
1.5× larger
BGC
$955.5M
$622.0M
RPRX
Growing faster (revenue YoY)
BGC
BGC
+39.0% gap
BGC
43.8%
4.8%
RPRX
Higher net margin
RPRX
RPRX
26.0% more per $
RPRX
34.4%
8.4%
BGC
Faster 2-yr revenue CAGR
BGC
BGC
Annualised
BGC
48.2%
4.6%
RPRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BGC
BGC
RPRX
RPRX
Revenue
$955.5M
$622.0M
Net Profit
$80.6M
$214.2M
Gross Margin
Operating Margin
62.4%
Net Margin
8.4%
34.4%
Revenue YoY
43.8%
4.8%
Net Profit YoY
2.9%
EPS (diluted)
$0.17
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGC
BGC
RPRX
RPRX
Q1 26
$955.5M
Q4 25
$638.6M
$622.0M
Q3 25
$620.8M
$609.3M
Q2 25
$648.0M
$578.7M
Q1 25
$534.6M
$568.2M
Q4 24
$475.2M
$593.6M
Q3 24
$448.9M
$564.7M
Q2 24
$435.0M
$537.3M
Net Profit
BGC
BGC
RPRX
RPRX
Q1 26
$80.6M
Q4 25
$14.4M
$214.2M
Q3 25
$27.9M
$288.2M
Q2 25
$57.5M
$30.2M
Q1 25
$55.2M
$238.3M
Q4 24
$25.2M
$208.2M
Q3 24
$14.7M
$544.0M
Q2 24
$37.8M
$102.0M
Operating Margin
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
3.9%
62.4%
Q3 25
5.4%
70.1%
Q2 25
11.6%
36.3%
Q1 25
15.0%
94.0%
Q4 24
5.7%
60.9%
Q3 24
4.4%
Q2 24
12.7%
50.2%
Net Margin
BGC
BGC
RPRX
RPRX
Q1 26
8.4%
Q4 25
2.3%
34.4%
Q3 25
4.5%
47.3%
Q2 25
8.9%
5.2%
Q1 25
10.3%
41.9%
Q4 24
5.3%
35.1%
Q3 24
3.3%
96.3%
Q2 24
8.7%
19.0%
EPS (diluted)
BGC
BGC
RPRX
RPRX
Q1 26
$0.17
Q4 25
$0.03
$0.49
Q3 25
$0.06
$0.67
Q2 25
$0.11
$0.07
Q1 25
$0.11
$0.55
Q4 24
$0.04
$0.46
Q3 24
$0.03
$1.21
Q2 24
$0.08
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGC
BGC
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$781.0M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$1.1B
$9.7B
Total Assets
$5.9B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGC
BGC
RPRX
RPRX
Q1 26
$781.0M
Q4 25
$851.5M
$618.7M
Q3 25
$774.9M
$938.9M
Q2 25
$827.8M
$631.9M
Q1 25
$966.4M
$1.1B
Q4 24
$711.6M
$929.0M
Q3 24
$563.5M
$950.1M
Q2 24
$571.7M
$1.8B
Total Debt
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
$1.5B
$9.0B
Q3 25
$1.8B
$8.9B
Q2 25
$1.8B
$8.0B
Q1 25
$1.1B
$7.6B
Q4 24
$1.1B
$7.6B
Q3 24
$1.4B
$7.6B
Q2 24
$1.4B
$7.6B
Stockholders' Equity
BGC
BGC
RPRX
RPRX
Q1 26
$1.1B
Q4 25
$972.5M
$9.7B
Q3 25
$965.3M
$9.6B
Q2 25
$930.5M
$9.5B
Q1 25
$963.8M
$9.8B
Q4 24
$898.5M
$10.3B
Q3 24
$860.1M
$10.3B
Q2 24
$858.1M
$9.8B
Total Assets
BGC
BGC
RPRX
RPRX
Q1 26
$5.9B
Q4 25
$4.4B
$19.6B
Q3 25
$5.8B
$19.3B
Q2 25
$4.9B
$18.3B
Q1 25
$4.9B
$17.6B
Q4 24
$3.6B
$18.2B
Q3 24
$4.4B
$18.0B
Q2 24
$4.3B
$17.7B
Debt / Equity
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
1.58×
0.92×
Q3 25
1.90×
0.93×
Q2 25
1.97×
0.84×
Q1 25
1.19×
0.78×
Q4 24
1.27×
0.74×
Q3 24
1.68×
0.74×
Q2 24
1.68×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGC
BGC
RPRX
RPRX
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
$180.4M
$827.1M
Q3 25
$141.9M
$702.6M
Q2 25
$71.2M
$364.0M
Q1 25
$839.0K
$596.1M
Q4 24
$251.9M
$742.5M
Q3 24
$88.3M
$703.6M
Q2 24
$-53.0M
$658.2M
Free Cash Flow
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
$175.1M
Q3 25
$137.2M
Q2 25
$65.0M
Q1 25
$-4.4M
Q4 24
$245.6M
Q3 24
$78.8M
Q2 24
$-63.5M
FCF Margin
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
27.4%
Q3 25
22.1%
Q2 25
10.0%
Q1 25
-0.8%
Q4 24
51.7%
Q3 24
17.5%
Q2 24
-14.6%
Capex Intensity
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
0.8%
Q3 25
0.8%
Q2 25
1.0%
Q1 25
1.0%
Q4 24
1.3%
Q3 24
2.1%
Q2 24
2.4%
Cash Conversion
BGC
BGC
RPRX
RPRX
Q1 26
Q4 25
12.55×
3.86×
Q3 25
5.09×
2.44×
Q2 25
1.24×
12.06×
Q1 25
0.02×
2.50×
Q4 24
9.99×
3.57×
Q3 24
5.99×
1.29×
Q2 24
-1.40×
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGC
BGC

Commissions$752.9M79%
Principal transactions$142.9M15%
Data, network and post-trade$34.5M4%
Other revenues$10.3M1%
Fees from related parties$4.3M0%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons